Brooke A. Meyers

BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments

Anne M. Walling, Rachael Sak, Samuel A. Skootsky, Neil Wenger et autres

us (code pays fourni par la source)

Abstract 5529: Development and characterization of BRAF/MEK inhibitor resistant anaplastic thyroid carcinoma patient-derived xenograft and cell line models

Ahmad Abubaker, Meredith A. Miller, Ying C. Henderson, Brooke A. Meyers et autres

Abstract Introduction: Anaplastic Thyroid Carcinoma (ATC) is one of the deadliest malignancies with 5-month median overall survival (OS). Treatment of BRAFV600E-mutated (BRAFm) ATC with BRAF/MEK inhibitors (BRAF/MEKi) revolutionized disease management and improved median OS to 16 months for this subgroup. However, like …

us (code pays fourni par la source)

Abstract 4304: Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma

Johnathon Lynn Rose, Sanjana Srinivasan, Meng He, Rosalba Minelli et autres

Abstract Uveal melanoma (UM) is a rare and lethal tumor characterized by mutually exclusive activating mutations in GNAQ and GNA11, secondary mutations in EIF1AX, SF3B1 and BAP1, and a late-stage chromosome 3 copy-number (CN) loss event. Importantly, chromosome 3 CN loss is …

us, it (code pays fourni par la source)

Abstract 94: Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma

Johnathon Lynn Rose, Sanjana Srinivasan, Meng He, Rosalba Minelli et autres

Abstract Uveal melanoma (UM) is a rare and lethal malignancy with very limited therapeutic options characterized by mutually exclusive activating mutations in GNAQ and GNA11, resulting in overactive proliferative signaling of Gαq/11 heterotrimeric G proteins. Additionally, tumors typically present with mutually exclusive …

us (code pays fourni par la source)

Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard et autres

Abstract Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full activation of the MAPK pathway. SHP2 inhibition has demonstrated tumor growth inhibition in RTK-activated cancers in preclinical …

Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard et autres

Abstract Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full activation of the MAPK pathway. SHP2 inhibition has demonstrated tumor growth inhibition in RTK-activated cancers in preclinical …

Supplementary information from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard et autres

Supplementary Materials and Methods Supplementary References Tables S1 to S3 and legends Figures S1 to S4 and legends

Supplementary information from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard et autres

Supplementary Materials and Methods Supplementary References Tables S1 to S3 and legends Figures S1 to S4 and legends

CCDC 2191608: Experimental Crystal Structure Determination

Barbara Czakó, Yuting Sun, Timothy J. McAfoos, Jason B. Cross et autres

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, …

Developing an IF panel to examine Cyclin and CDK interactions in a Pancreatic Adenocarcinoma Patient Derived Xenograph.

Nathalie A. Garza, Ethan D. Marszalek, Alyssa M. Machado, Brooke A. Meyers et autres

Goes Here Materials and Methods siRNA experiments:• CCNA2 and Non-targeting controls(NTC) siRNAs were acquired from Dharmacon.• siRNA transfections were performed using DharmaFect formulation to optimize seeding density for 10 cm plates.

us (code pays fourni par la source)

Discovery of 6-[(3 S ,4 S )-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Barbara Czakó, Yuting Sun, Timothy J. McAfoos, Jason B. Cross et autres

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its …

us (code pays fourni par la source)

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard et autres

Abstract Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full activation of the MAPK pathway. SHP2 inhibition has demonstrated tumor growth inhibition in RTK-activated cancers in preclinical …

us (code pays fourni par la source)